These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38604294)

  • 21. Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.
    Alghamdi J; Matou-Nasri S; Alghamdi F; Alghamdi S; Alfadhel M; Padmanabhan S
    Int J Neuropsychopharmacol; 2018 Dec; 21(12):1067-1075. PubMed ID: 29986042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
    Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
    Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
    Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
    Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
    Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
    PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
    Qiao L; Lv S; Meng K; Yang J
    Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy.
    Krittanawong C; Khawaja M; Rosenson RS; Amos CI; Nambi V; Lavie CJ; Virani SS
    Curr Probl Cardiol; 2022 Jul; 47(7):101043. PubMed ID: 34780866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
    Carugo S; Sirtori CR; Corsini A; Tokgozoglu L; Ruscica M
    Curr Atheroscler Rep; 2022 Dec; 24(12):995-1004. PubMed ID: 36383291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study.
    Luo S; Lam HS; Chan YH; Tang CSM; He B; Kwok MK; Leung GM; Schooling CM; Au Yeung SL
    BMC Med; 2023 Oct; 21(1):410. PubMed ID: 37904165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
    Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
    PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between Lipid-Lowering Drugs and Traumatic Subdural Hemorrhage: A Mendelian Randomization Study.
    Chen K; Li H; Chen Y; Huang H; Wei L
    J Integr Neurosci; 2024 Apr; 23(4):76. PubMed ID: 38682216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome.
    Moroni F; Ayers MP; Dixon DL; Abbate A
    J Cardiovasc Pharmacol; 2023 May; 81(5):336-338. PubMed ID: 37043382
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-effectiveness evaluation of the use of PCSK9 inhibitors.
    Civeira F; Pedro-Botet J
    Endocrinol Diabetes Nutr (Engl Ed); 2021; 68(6):369-371. PubMed ID: 34742469
    [No Abstract]   [Full Text] [Related]  

  • 33. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.
    Zhao SS; Yiu ZZN; Barton A; Bowes J
    JAMA Dermatol; 2023 Mar; 159(3):275-280. PubMed ID: 36696131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
    Canonico ME; Hess CN; Cannon CP
    Curr Atheroscler Rep; 2023 Jul; 25(7):381-389. PubMed ID: 37223853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment.
    Sliz E; Kettunen J; Holmes MV; Williams CO; Boachie C; Wang Q; Männikkö M; Sebert S; Walters R; Lin K; Millwood IY; Clarke R; Li L; Rankin N; Welsh P; Delles C; Jukema JW; Trompet S; Ford I; Perola M; Salomaa V; Järvelin MR; Chen Z; Lawlor DA; Ala-Korpela M; Danesh J; Davey Smith G; Sattar N; Butterworth A; Würtz P
    Circulation; 2018 Nov; 138(22):2499-2512. PubMed ID: 30524137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
    Liang Z; Zhao L; Lou Y; Liu S
    QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
    Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
    Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In search of the pleiotropic effects of PCSK9 inhibitors.
    Räber L; Ueki Y
    EuroIntervention; 2022 Oct; 18(8):e609-e610. PubMed ID: 36205734
    [No Abstract]   [Full Text] [Related]  

  • 40. PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives.
    Nicholls SJ
    Kardiol Pol; 2023; 81(2):115-122. PubMed ID: 36739653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.